Interleukin (IL)-23 and IL-27 are pro-inflammatory cytokines that share functional and structural similarities and may exert anti-tumor activities against solid and hematological malignancies. Here, we asked whether IL-23 and IL-27, alone or in combination, may act directly against human follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) cells.
INTRODUCTION
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common type of Non-Hodgkin's lymphomas accounting 30% and 20% of cases in adults, respectively.
1 FL and DLBCL arise from malignant transformation of germinal center B cells often promoted by chromosome translocations and by multistep accumulation of further genetic alterations. The clinical course of FL and DLBCL is heterogeneous. Some FL patients show slow progression or stable disease over many years, whereas others patients are characterized by rapid progression, often from FL to aggressive DLBCL, 2 and by early death. 3 Outcome of DLBCL patients differs among DLBCL subtypes, 1 ranging from good therapeutic response to high frequency of relapse and death.
Chemotherapy 4 and immunologic therapies based on antibodies to B cells, 5, 6 alone or in combination, 7, 8 represent the main therapeutic approaches used in the management of FL/DLBCL.
Although some encouraging results in terms of median survival 6 have been obtained, tumor progression to more aggressive disease and development of resistance to standard therapeutic protocols represent the major causes of patient death. Thus, development of new therapeutic strategies is needed in order to obtain durable or complete remissions and extended quality of life. In the past years, some clinical studies using cytokines in FL therapy, including interleukin (IL)-12, IL-3 and IL-2 alone or in combination with rituximab, have been tried 9 --11 with limited results. More recently, it has been demonstrated that IL-21 induces apoptosis of FL and DLBCL cells in vitro through downregulation of Bcl-2.
12 --14 Notably, the pro-apoptotic activity of IL-21 is directed to FL cells that expressed IL-21 receptor (R).
Here, we asked whether IL-23 and IL-27, two immunomodulatory cytokines 15 with anti-tumor properties, 16 --22 may function against FL and DLBCL cells and we investigated the potential mechanisms involved.
IL-23 is composed of the promiscuous IL-12p40 and the exclusive p19 subunits. 23 IL-27 is composed of the EBV-induced 3 and p28 subunits 24 that are homologs to the p40 and p35 chains of IL-12, respectively. Similarly, IL-23R is composed of the IL-12Rb1 chain and the unique IL-23R chain, 25 that associate with Jak2 and STAT3, whereas IL-27R contains the unique receptor subunit WSX-1 also known as IL-27Ra/TCCR, paired with the gp130 chain. 26 Both chains of IL-23 and of IL-27 R are necessary for the corresponding cytokine signal transduction. 25, 26 IL-23 and IL-27 are mainly produced by antigen-presenting cells and have an important role in regulation of immune responses. 15 Furthermore, similar to IL-12, they exert anti-tumor activities in different tumors through indirect mechanisms such as induction of NK and CTL response or inhibition of angiogenesis. 19, 20, 27 Moreover, recent studies have shown that these cytokines can exert direct anti-tumor activity against solid and hematological malignancies. 17, 21, 22, 28, 29 Although the anti-tumor activity of IL-23 is quite controversial, 18, 30, 31 we 21 have demonstrated that IL-23 shows anti-leukemic effects by dampening directly pediatric B-acute lymphoblastic leukemia cell growth both in vitro and in vivo through the inhibition of cell proliferation and induction of apoptosis. In addition, we recently demonstrated that IL-27 acts as multifunctional anti-tumor agent in multiple myeloma (MM) 22 and inhibits acute lymphoblastic leukemia cell spreading in a pre-clinical model. 32 With this background, we here investigated (i) the expression of both chains of IL-23 and IL-27 R in human primary FL and DLBCL cells and cell lines, (ii) the potential anti-tumor activities of IL-23 and IL-27 against FL and DLBCL cells and (iii) the mechanisms involved.
SUBJECTS AND METHODS Patients
Lymph nodes biopsies highly infiltrated with neoplastic cells (495%) from 12 FL and 5 DLBCL patients were obtained for diagnostic procedures and after informed consent. FL/DLBCL diagnosis was based on clinical morphologic, immunophenotypic and molecular criteria according to the revised WHO classification. 33 All patients were at diagnosis and untreated at the time of the study. The main demographic and clinical features of patients are summarized in Table 1 . The study design was approved by the institutional review board of the National Institute of Cancer Research, Genova, Italy. Lymph node cell suspensions were obtained by Ficoll Hypaque (Seromed Biochrom KG, Berlin, Germany) density-gradient centrifugation from fresh biopsies and neoplastic cells were identified as CD19 þ CD10 þ CD38 þ cells, by flow cytometry. 33 Purified FL/DLBCL cell suspensions were obtained by negative immunomagnetic selection using the Easy step Human B cell enrichment kit (Stem cell Technologies, Vancouver, Canada). The purity of FL/DLBCL cell suspensions ranged from 96 to 99%.
Cell culture, reagents and antibodies for flow cytometry
The human SU-DHL-4, DOHH-2, Karpas-422, and OCY-LY8 cell lines bearing the t(14;18) translocation and primary FL/DLBCL were cultured in RPMI 1640 medium with 10% fetal calf serum (Seromed Biochrom KG).
Human recombinant (hr) IL-23 and IL-27 were from R&D Systems, Inc. (Minneapolis, MN, USA). Fluorochrome-conjugated CD19, CD10 and CD38 monoclonal antibodies (mAb) were from BD Biosciences (San Josè , CA, USA). Fluorochrome-conjugated anti-IL-23R, gp130, IL-12Rb1 and mouse immunoglobulin (Ig)G 2b anti-human WSX-1 were from R&D Systems. PE-conjugated Ig swine anti-mouse IgG 2b were from Southern Biotechnology, Inc. (Birmingham, AL, USA) and fluorochrome-conjugated antiKi67 was from Dako (Glostrup, Denmark). Alexa fluor 647-conjugated anti-human vascular endothelial growth factor (VEGF)R2 was from Biolegend (San Diego, CA, USA). Rabbit mAb to human SPHK1 and the appropriate secondary fluorochrome-conjugated antibody were from ABCAM (Cambridge, UK). Intracellular staining for detection of SPHK1 was performed as described. 34 Isotype-matched antibodies of irrelevant specificity (Invitrogen, Camarillo, CA, USA) were used as controls. Cells were scored by FACS Calibur analyzer (BD Biosciences) and data processed using CellQuest software (BD Biosciences).
Signaling pathway IL-23 and IL-27 signaling pathways were investigated in purified lymphoma cells from three FL (Pt #9, #14 and #16) and three DLBCL patients, by flow cytometry (Pt #4, #8 and #17). Signal transduction was investigated using the following Alexa 488 fluorochrome-conjugated mAbs: anti phospho-STAT1 (clone 58D6), -STAT3 (clone D3A7), -STAT5 (clone C71E5, Cell Signalling Technology, Inc., Danvers, MA, USA) and fluorochrome-matched isotype antibodies (Beckman Coulter, Miami, FL, USA). Cells were resuspended in RPMI 10% AB serum and incubated with medium alone, hrIL-23 or hrIL-27 for 30 min at 37 1C, 5% CO 2 , and then processed following the instructions of the manufacturer. Cells were scored by Gallios flow cytometry, 10 4 events were acquired and analyzed using Kaluza software (Beckman Coulter, Brea, CA, USA). Data were expressed as the mean relative of fluorescence intensity (MRFI), calculated as follows: fluorescence intensity obtained with specific mAb/fluorescence intensity obtained with irrelevant isotype-matched mAb.
Cell proliferation and apoptosis assays SU-DHL-4, DOHH-2, Karpas-422 and OCI-LY8 cell lines were cultured 6, 24, 48, 72 and 96 h with or without IL-23 (100 ng/ml) or IL-27 (50 ng/ml) or IL-23 þ IL-27, the optimal concentrations established by previous results and confirmed following titration experiments. 21, 22 Purified FL/DLBCL cells from Pt #1 --6, #8 and #12 were co-cultured with murine fibroblast NIH-3T3 transfected with pIRES-neo bicystronic plasmid vector carrying the human CD40L gene (3T3/CD40L) (kindly provided by Dr Franco Fais, Department of Experimental Medicine, University of Genova). The same cells transfected with the empty vector (3T3/empty) were used as controls. Briefly, 3T3/CD40L cells were first irradiated at 50 Gy and subsequently plated in 12- Some of the purified lymphoma cell samples studied for modulation of cell proliferation were tested for apoptosis (Pt #1 --2, #8 and #12) at 48 h using the Annexin V/FITC kit (Immunostep S.I., Salamanca, Spain) and analyzed by flow cytometry.
All flow cytometric analyses were performed on total purified FL or DLBCL cells.
Chorioallantoic membrane (CAM) assay CAM assay was performed as reported. 35 Sponges were loaded with: 1 ml PBS (negative control); 1 ml PBS with 250 ng VEGF (R&D Systems; positive control); 1 ml conditioned medium from FL cell lines or three purified primary FL (Pt #7, #10 and #15) or three purified DLBCL samples (Pt #5, #12 and #17) cultured 36 h with or without IL-23 or IL-27; IL-27 or IL-23 diluted in medium at the same final concentration used to treat tumor cells; 250 ng VEGF þ IL-27 or IL-23 diluted in medium at the same final concentration used to treat tumor cells.
Mice studies
Four-to six-week-old severe combined immunodeficiency (SCID)-nonobese diabetic (NOD) mice (Harlan Laboratories, Udine, Italy) were housed under specific pathogen-free conditions. All procedures involving animals were performed in the respect of the National and International regulations (D.l.vo 27/01/1992, n.116, European Economic Community Council Directive 86/609, OJL 358, December 1, 1987) .
Four groups of 10 animals each were injected subcutaneously (s.c.) with 5 Â 10 6 SU-DHL-4 cells and treated s.c. with PBS (control) or hrIL-23, hrIL-27 or hrIL-23 þ hrIL-27 (1 mg/mouse/dose for each cytokine), three doses per week starting from 8 h after tumor-cell inoculation. Twenty-eight days after tumor-cell inoculation, mice were killed, as they developed signs of poor health, autopsies were carried out, tumor masses were measured as described 36 and subjected to histological, molecular and flow-cytometric analyses.
In additional experiments using three mice for each group, we killed control and treated mice at day 10, 18 and 28 after cell inoculation in order to evaluate the time course curve of tumor growth.
Morphologic and immunohistochemical analyses
Tissue samples were formalin-fixed, paraffin-embedded, sectioned at 4 mm thick sections, and stained with Hematoxylin and Eosin. For immunohistochemistry, formalin-fixed, paraffin-embedded sections were immunostained with rabbit anti-human/mouse laminin (Biogenex, San Ramon, CA, USA), mouse anti-Ki67 (Dako), rabbit anti-human IL-6 (Abcam) or rabbit anti-human VEGF-C (Zymed, San Francisco, CA, USA), rat anti-mouse F4/80 (Caltag Laboratories Inc., Burlingame, CA, USA) and rat anti-mouse CD49b (Pan-NK cells, clone DX5) (Pharmingen, San Diego, CA, USA) Abs. After washing, sections were overlaid with goat anti-rabbit Ig conjugated to peroxidase-labelled dextran (EnVision þ Peroxidase, rabbit/mouse) (Dakocytomation) for 30 min. Unbound Ig was removed by washing and slides were incubated with ABC (avidin-biotin complex)/alkaline phosphatase (Dako) for 30 min, then sections were counterstained with hematoxylin and eosin.
Laminin positive vessels were counted in eight randomly chosen fields under a microscope Â 400 field ( Â 40 objective and Â 10 ocular lens; 0.180 mm 2 per field). The rates of proliferating cells, as assessed by immunoreactivity for Ki67, were determined by counting the number of positive cells/number of total cells in the viable neoplastic tissue under a microscope Â 400 field ( Â 40 objective and Â 10 ocular lens; 0.120 mm 2 per field).
PCR-array
RNA was extracted from tumors removed from SCID-NOD mice treated with PBS (controls) or hrIL-27 (1 mg/mouse/dose), from three primarypurified DLBCL (Pt #5, #12 and #17) and three purified FL samples (Pt #7, #10 and #15) cultured 36 h with or without 50 ng/ml IL-27, using TRIZOL reagent (Invitrogen). Contaminant genomic DNA was removed by Dnase treatment (Qiagen GmbH, Hilden, Germany). RNA was reverse-transcribed by the RT 2 First Strand cDNA Synthesis kit (SABioscience, Frederick, MD, USA). Human Angiogenesis RT 2 PCR Array and RT 2 Real-Time SyBR Green/ ROX PCR Mix were from SABioscience. PCR was performed on ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). Results were normalized on the median value of a set of housekeeping genes. Changes in gene expression between IL-27-treated and control samples were calculated using the DDC t method. 37 Results from three different IL-27-treated and control samples were pooled and analyzed by software provided by the manufacturer. A significant threshold of four-fold change in gene expression corresponded to Po0.001.
Statistical methods
Student's t-test was used for evaluation of differences in the number of vessels formed in CAM assay, number of Ki67 positive cells, apoptotic cells and tumor microvessels in immuno-histological studies. Differences in tumor volume, proliferative cells, STAT-phosphorylation and IL-23R or WSX-1 expression were calculated using Mann --Whitney test comparing two independent samples, with 99% confidence interval. Quantitative studies of stained sections were performed independently by two pathologists in a blind fashion. Eight fields were examined for each tumor section and three sections per tumor (three cytokine treated vs three PBS treated). All statistical tests were two tailed and a P-value o0.05 was considered statistically significant. Figure 1a ). Neoplastic cells in unfractionated FL samples were identified as CD19
RESULTS

Expression and function of IL-23 and IL-27 R in primary FL
The IL-23R and WSX-1 were studied in unfractionated lymphoma samples by four-color staining analyzing the cytokine R expression on gated CD19 þ CD10 þ CD38 þ cells. The other two chains of IL-23 and IL-27 R, that is, IL-12Rb1 and gp130, respectively, were expressed by FL and DLBCL cells (Figure 1a) , indicating that these cells may be responsive to the corresponding cytokines.
In order to elucidate the down-stream pathway induced by IL-23 and IL-27, we analyzed the ability of each cytokine to induce activation of specific STAT molecules in lymphoma cells, as reported for human tonsil B cells 38 and plasmacells. 34 To this end, three purified FL and three purified DLBCL cell suspensions were treated with medium, IL-23 or IL-27 and tested for intracellular phosphorylation of STAT1, Supplementary Figure 2A) or the IL-23R and WSX-1 expression levels in FL/DLBCL cells (Supplementary Figure 2B) , compared with that observed in the same samples at diagnosis. In addition, no differences were observed in terms of CD19, CD10, CD38, WSX-1 or IL-23R expression upon IL-23 or IL-27 treatment ( Supplementary Figures 2A and B) . These experiments demonstrated that IL-23 and, more marginally, IL-27 significantly (P ¼ 0.0056 and P ¼ 0.0219, respectively) reduced proliferation of primary-purified FL and DLBCL cells after 48 h treatment (Figure 2A, Figure 2B ). Moreover, IL-23 and, more marginally, IL-27 inhibited the transition into phase S of FL cells ( Figure 2B ). Combined treatment with IL-23 and IL-27 did not amplify such effects.
Finally, 48 h of IL-23 or IL-27 treatment did not significantly induce apoptosis (Supplementary Figure 2D) . Concentrations o 100 ng/ ml of IL-23 or 50 ng/ml of IL-27 treatment did not affect proliferation or apoptosis of purified FL/DLBCL cells (data not shown). 40 --44 Thus, we asked whether IL-23 and IL-27 may influence the angiogenic potential of FL/DLBCL cells, using the in vivo CAM assay. Thus, purified FL (n ¼ 3) and DLBCL (n ¼ 3) were incubated 36 h with medium, IL-23 or IL-27. CAM treated with sponges loaded with VEGF (positive control) or conditioned medium from purified FL or DLBCL cells were surrounded by allantoic vessels developing radially towards the implant in a 'spoked-wheel' pattern. In the representative experiment shown in Figure 2C , left upper panel, the mean number of vessels formed by supernatant from FL cells was 24 ± 4, whereas that formed by VEGF was 30 ± 5 (data not shown). When the supernatant from IL-27-treated cells from the same patient was tested, a significant (Po0.001) reduction of the angiogenic response was appreciable (mean number of vessels ¼ 12 ± 4; Figure 2C , left lower panel), whereas no effect was detected upon incubation with supernatant from IL-23-treated cells ( Figure 2C , left middle panel; mean number of vessels ¼ 20 ± 2). Supernatant from FL cells treated with both IL-23 and IL-27 induced a reduction of microvessel formation comparable to that observed upon IL-27 incubation alone (data not shown), confirming that IL-27, but not IL-23, possess anti-angiogenic properties against FL cells. Similar results were obtained using three purified DLBCL cell samples (one experiment is shown in Figure 2C , right panels). In addition, no vascular reaction was detected around the sponges upon exposure to IL-27 or IL-23 diluted in medium at the same final concentration used to treat tumor cells (mean number of vessels ¼ 7±3 with or without cytokines). Finally, medium containing IL-27 did not inhibit angiogenesis induced by VEGF (data not shown), indicating that IL-27 itself is not capable to inhibit angiogenesis.
To investigate more closely the molecular mechanisms underlying the anti-angiogenic effect of IL-27 against FL and DLBCL cells, we analyzed medium or IL-27-treated cells for modulation of gene expression using the Human Angiogenesis PCR-Array kit that allows to detect 84 human angiogenesis-related genes. We found that in purified FL cells, IL-27 downregulated different proangiogenic molecules such as SPHK1, VEGFR2, ANGPTL4, CXCL2, EFNA3, IL1B and PLXDC1 ( Figure 2D ). By contrast, in primary DLBCL cells IL-27 downregulated the pro-angiogenic cadherin-5, COL4A3 and S1PR1 ( Figure 2D ). However, in DLBCL cells, IL-27 also induced the downregulation of the anti-angiogenic CXCL9 and the upregulation of pro-angiogenic factors such as ECGF-1, HGF, IGF-1 and MDK. Comparative analysis of angiogenesis-related genes modulated by IL-27 in FL and DLBCL cells is reported in Figure 2D . All the other genes included in the angiogenesis PCR array kit not shown in Figure 2D were found to be not significantly regulated by IL-27 treatment (data not shown). It is of note that IL-27 did not modulate IFN-g expression in primary FL and DLBCL cells.
Finally, we investigated whether downregulation of gene expression upon IL-27 treatment effectively translated into reduction of the corresponding protein. To this end, three purified FL cell samples were tested by flow cytometry for modulation of expression of SPHK1 and VEGFR2. The choice of these two molecules arises from the consideration that SPKH1 was found to be the most downregulated gene by PCR array and that expression level of VEGFR2 represents a prognostic factor in non-Hodgkin's lymphomas. 45 These experiments revealed that SPHK1 protein expression was significantly (P ¼ 0.0453) reduced in FL cells treated with IL-27 as compared with untreated cells (box on the right of Figure 2D ). By contrast, surface expression of VEGFR2 was not modulated significantly by IL-27 (data not shown).
IL-23 and IL-27 inhibit tumorigenicity of SU-DHL-4 cells in SCID-NOD mice and show synergistic effects
The in vivo anti-tumor activity of IL-23 and IL-27 against FL/DLBCL cells was studied using SCID-NOD mice injected s.c. with the human SU-DHL-4 cell line. The latter cells were selected, as they expressed high levels of both IL-23R and IL-27R and were similar to primary FL/DLBCL cells in terms of response to IL-23 and IL-27 (see Supplementary Material). Four groups of 10 animals each were inoculated s.c. with 5 Â 10 6 SU-DHL-4 cells and treated s.c. three doses per week with: (i) PBS (controls), (ii) 1 mg/dose hrIL-23, (iii) 1 mg/dose hrIL-27 and (iv) hrIL-23 þ hrIL-27 (1 mg/dose each).
On day 10, tumors developed in all groups of mice did not significantly differ in terms of tumor volume ( Figure 3A) . By contrast, at day 18, tumors from hrIL-23, hrIL-27 or hrIL-23 þ hrIL-27 treated mice showed a significant reduction as compared to those grown from controls ( Figure 3A) . In additional experiments, tumor masses were explanted and subjected to histological and molecular analyses at day 28. At this time point, mice treated with hrIL-23, hrIL-27 and hrIL-23 þ hrIL-27 developed tumors significantly smaller than mice receiving PBS (n ¼ 10 for each group, Figure 3B ). Furthermore, combined administration of the two cytokines dampened significantly tumor growth as compared with IL-23 and IL-27 treatment alone ( Figure 3B ).
Histological and immunohistochemical analyses ( Figure 3C ) demonstrated that tumors from control mice was formed by a mixture of small and large lymphoid cells with centrocytes and centroblasts morphology (panel a). The large lymphoid cells showed ground glass nuclei characterized by dispersed chromatin and prominent nucleoli. Mitotic features were frequently found. Table 2 . Infiltration by host monocytes/macrophages (assessed by F4/80 Ab) and NK cells (assessed by CD49b Ab) were scarce to absent, within 28-day tumors developed in mice treated with hrIL-23 or hrIL-27 or both cytokines (data not shown), and were comparable to those observed in tumors from PBS-treated mice. In addition, histological analyses revealed that polymorphonuclear cells, identified by hematoxylin and eosin staining for the presence of multilobed nucleus and tiny light staining cytoplasmic granules, were undetectable in all tumor masses.
To gain more insight into the molecular mechanisms underlying the anti-angiogenic effect of IL-27, we analyzed the expression of 84 angiogenesis-related genes by PCR Array in tumors explanted from PBS and hrIL-27-treated mice. As shown in Figure 3D , IL-27 downregulated several pro-angiogic factors, whereas up-regulated some anti-angiogenic molecules. In addition, IL-27 also induced a downregulation of some anti-angiogenic factors (CXCL10 and TIMP2) and upregulation of VEGF-D. Similar to that observed in vitro, IL-27 did not modulate IFN-g expression.
As VEGF-C and IL-6 were two of the most strongly downregulated pro-angiogenic genes in our in vivo model, we tested whether IL-27 downregulated VEGF-C and IL-6 also at protein level. To this end, immunohistochemical analysis was performed on tumors from hrIL-27 and PBS-treated mice. Such analysis revealed that tumor cells from PBS-treated mice showed a moderate intra-cytoplasmatic expression of VEGF-C ( Figure 3E , panel a) and a distinct expression of IL-6 ( Figure 3F, panel a) , whereas hrIL-27-treated mice showed barely detectable expression levels of VEGF-C ( Figure 3E In vitro experiments demonstrated that IL-23, and more marginally IL-27, inhibited lymphoma cell proliferation, whereas IL-27 primarily dampened the angiogenic potential of primary FL and DLBCL cells. However, no additive or synergistic anti-tumor effects were observed in vitro using combined treatment with both cytokines.
In vivo studies were performed using the SU-DHL-4 lymphoma cell line that was injected into SCID/NOD immunodeficient animals. These experiments allowed us to demonstrate that these cytokines reduced, in the absence of immune responses, lymphoma cell growth in vivo through two main different and independent mechanisms, namely inhibition of cell proliferation induced by IL-23 and reduction of angiogenesis mediated by IL-27. Due to this feature, combined treatment with IL-23 and IL-27 significantly augmented FL growth inhibition in vivo as compared with IL-23 and IL-27 treatment alone.
The anti-angiogenic activity of IL-27 represents an important issue as several studies reported that increased angiogenesis is a marker of shorter survival and may promote progression to aggressive disease. 42, 45 In this context, here we show that IL-27 inhibits the ability of lymphoma cells to form new vessels by modulating several molecules involved in the angiogenic process both in vitro and in vivo. In vitro experiments revealed that in primary FL cells, IL-27 downregulated exclusively the expression of pro-angiogenic genes. By contrast, in DLBCL cells, the IL-27 driven inhibition of pro-angiogenic genes was paralleled by a modest upregulation of some pro-angiogenic molecules and downregulation of the anti-angiogenic CXCL9 chemokine. Although the latter finding may appear surprising, it is to mention that the inhibition of angiogenesis observed in the CAM assay using primary DLBCL cells may result from a complex balance between angiogenic and angiostatic molecules that are modulated by the cytokine, in which downregulation of pro-angiogenic factors exerts a prominent role. In addition, the upregulation of some pro-angiogenic genes driven by IL-27 in the DLBCL cells possibly witnesses an attempt of malignant cells to counterbalance the reduced expression of pro-angiogenic molecules.
Furthermore, the finding that the pro-and anti-angiogenic factors modulated in vitro by the cytokine in primary FL and DLBCL cells were different may be conceivably related to the intrinsic features of the two lymphoma subtypes.
In vivo studies showed that VEGF-C and IL-6 were strongly decreased upon IL-27 treatment, suggesting a critical involvement of these mediators in the anti-tumor activity of the cytokine. In this connection, the expression of IL-6 and VEGF was reported to be upregulated in FL and DLBCL patients compared with normal individuals, thus demonstrating to have prognostic value. 45 --48 In addition, these molecules function not only as angiogenic factor but also as growth factors that support lymphoma cell proliferation through autocrine pathways. 49, 50 It is worth mentioning that IL-23 and IL-27 may be active also on murine cells, but the following findings support the conclusion that, in our model, these cytokines targeted directly human lymphoma cells: (i) the in vivo anti-tumor mechanisms operated by these cytokines were overlapping with those detected in vitro, and (ii) tumor infiltration with host mononuclear cells was scarce to absent and polymorphonuclear cells were virtually undetectable. Moreover, we have previously demonstrated that also in SCID/ NOD mice injected with MM cells, hrIL-27 never recruited host immune cells neither affected murine vessel formation, 22 thus indicating that the anti-tumor activity driven by this cytokine was primarily dependent on its ability to function directly on tumor cells.
Taking together, these findings highlight IL-23R and IL-27R as potential therapeutic target in human FL and DLBCL. This is of great relevance as development of novel targeted therapies may open new perspectives for treatment of indolent FL patients and for preventing relapse. Besides standard treatments, novel agents have been recently described to be potentially useful in FL therapy, 51 including molecules involved in apoptotic pathways.
--55
The use of IL-23 and IL-27 in cancer therapy has not yet been investigated, but some pre-clinical studies recently evaluated the efficacy and toxicity of these cytokines, providing important information for potential clinical applications. In one of these studies, a comparative analysis between IL-12, IL-23 and IL-27 was performed using a murine model of poorly immunogenic melanoma. 19 IL-23 and IL-27 inhibited melanoma growth by stimulating anti-tumor immune response and, compared with IL-12, systemic administration of IL-23 and IL-27 did not enhance IFN-g serum level, the main factor involved in toxicity onset. In this regard, we here reported that IL-27 did not modulate IFN-g expression. The finding is also supported by our previous results demonstrating that IL-27 treatment of MM cells upregulated CXCL10 and CXCL9 through IFN-g-independent mechanisms. 22 Another important issue that needs to be taken into account in view of the therapeutic use of IL-23 is represented by the ability of this cytokine to support the maintenance and homeostasis of T helper 17 (Th17) cells, whose role in cancer is actually a matter of active debate. 56 Th17 cells and Th17-associated cytokines were shown to have both anti-tumor and pro-tumor functions. 56 For example, it was reported that high levels of Th17-associated cytokines were detected in MM patients compared with healthy donors and elevated IL-17 serum levels were correlated with stage II and III MM. 57 By contrast, in human carcinomas, high tumor infiltration by Th17 cells correlated positively with the presence of immune effector cells such as cytotoxic T lymphocytes and NK cells. 58, 59 Therefore, the relationship between Th17 cells and tumor immuno-pathology are highly dependent on tumor microenvironment 56 in which different immune cells take part including regulatory T cells and Th17 lymphocytes characterized by functional and phenotypic plasticity. 60 In this scenario, we can not predict if and how IL-23 administered in vivo can perturb the Treg/Th17 cell balance.
Taken together, our data suggested that IL-23 and IL-27 administered alone or in combination, may represent novel therapeutic agents in lymphoma therapy, whose feasibility is dependent by phase I/II studies testing toxicity/efficacy of the individual cytokines.
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